Suggested remit: To appraise the clinical and cost effectiveness of fedratinib within its marketing authorisation for disease related splenomegaly or symptoms from myelofibrosis.
Status In progress
Process STA 2018
ID number 1501

Provisional Schedule

Expected publication 24 March 2021

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
30 January 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of fedratinib for splenomegaly and symptoms in myelofibrosis. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early May 2020 when we will write to you about how you can get involved.
03 April 2019 - 01 May 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 June 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance